<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970044</url>
  </required_header>
  <id_info>
    <org_study_id>WCCR-2019-1</org_study_id>
    <nct_id>NCT03970044</nct_id>
  </id_info>
  <brief_title>Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.</brief_title>
  <official_title>Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Consano Clinical Research, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Consano Clinical Research, LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase IV, single site, randomized, open-label, parallel study comparing
      BYDUREON-BCise plus FARXIGA to BYDUREON-BCise alone and FARXIGA alone in patients diagnosed
      with Type 2 Diabetes Mellitus (T2DM) on a stable dose of metformin alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase IV, single site, randomized, open-label, 3 treatment group, parallel study
      comparing BYDUREON-BCiseTM plus FARXIGATM to BYDUREON-BCiseTM alone and FARXIGATM alone in
      patients diagnosed with Type 2 Diabetes Mellitus (T2DM) on a stable dose of metformin alone.

      Patients who meet all inclusion and none of the exclusion criteria will enter a 1-week
      Lead-in Period, during which patients will be given a blood glucose meter and fitted with a
      blinded Continuous Glucose Monitor (CGM) and undergo a 14-day CGM assessment.

      After the 1-week Lead-in Period, approximately 60 subjects will be randomized at a 1:1:1
      ratio to one of three open-label treatment arms to achieve approximately 20 subjects per
      treatment arm.

      The study consists of a 2-week Screening Period, a 1-week Lead-in Period, a 14-week
      open-label Treatment Period and a 10-week Follow-up Period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MAGE</measure>
    <time_frame>14 weeks</time_frame>
    <description>Compare the change in mean amplitude of glucose excursions from baseline to week 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change in fasting plasma glucose from baseline to week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change in HbA1c from baseline to week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change in weight from baseline to week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>14 weeks</time_frame>
    <description>Change in blood pressure from baseline to week 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Variability</measure>
    <time_frame>14 weeks</time_frame>
    <description>Variability in blood glucose from baseline to weeks 4, 10 and 14</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>24 Hour Mean Blood Glucose</measure>
    <time_frame>17 weeks</time_frame>
    <description>Change in 24 mean blood glucose at multiple time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Glucose Time In Range</measure>
    <time_frame>14 weeks</time_frame>
    <description>Measure the proportion of time patients who had plasma glucose measurements of: &lt;70 mg/dL, &gt;70 mg/dL and &lt;180 mg/dL or &gt;180 mg/dL</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Exenatide 2 mg plus Dapagaliflozin 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide extended release, 2 mg weekly, injected Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide 2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Exenatide extended release, 2 mg weekly, injected 14 weeks of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagaliflozin 10 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin, 10 mg once daily, orally 14 weeks of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide 2 MG</intervention_name>
    <description>Glucagon-like peptide-1 receptor</description>
    <arm_group_label>Exenatide 2 mg</arm_group_label>
    <arm_group_label>Exenatide 2 mg plus Dapagaliflozin 10 mg</arm_group_label>
    <other_name>Bydureon</other_name>
    <other_name>Bydureon BCise</other_name>
    <other_name>Byetta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10 MG</intervention_name>
    <description>sodium-glucose co-transporter 2 (SGLT2) inhibitor</description>
    <arm_group_label>Dapagaliflozin 10 mg</arm_group_label>
    <arm_group_label>Exenatide 2 mg plus Dapagaliflozin 10 mg</arm_group_label>
    <other_name>Farxiga 10 MG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed written consent prior to any tudy specific
             procedures

          -  Male or female, age 18 to 75 years

          -  Diagnosis of T2DM

          -  HbA1c &gt;7.5% and &lt;12% obtained at Screening

          -  Treated with a stable dose of metformin alone (&gt;1500 mg/day) or max tolerated dose for
             at least 8 weeks prior to Screening

          -  Body mass index (BMI) &lt;45 kg/m2

          -  Women of childbearing potential (WOCBP), defined as any female who has experienced
             menarche and who has not undergone surgical sterilization (hysterectomy or bilateral
             oophorectomy), must agree to use 2 medically accepted, effective methods of birth
             control (e.g., hormonal contraceptive, barrier contraceptive with additional
             spermicide, tubal ligation, or an intrauterine device) prior to IP administration and
             continuing throughout the study and continuing for 10 weeks after the intake of the
             last dose of IP

          -  Females who are postmenopausal must have been postmenopausal for &gt;1 year if they wish
             not to use contraceptives. If postmenopausal status is questionable, the patient's
             follicle-stimulating hormone level must be checked and must be elevated and consistent
             with postmenopausal levels (i.e., &gt;40 IU/L); otherwise these patients must agree to
             use contraceptives listed above

          -  Males who are sexually active with WOCBP must be surgically sterile or using an
             acceptable method of contraception (defined as barrier methods in conjunction with
             spermicides) for the duration of the study (from the time they sign consent) and for
             10 weeks following the last intake of IP to prevent pregnancy in a partner

        Exclusion Criteria:

          -  Involvement in the planning and/or conduct of the study (applies to both Investigator
             staff and/or staff at the study site)

          -  Previous enrolment in the present study

          -  Participation in a study within 30 days of planned enrolment in this study and at
             least 5 half-lives of the investigational product (IP) the patient received in a
             previous study

          -  Positive serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent
             units of human chorionic gonadotropin) within 24 hours prior to the start of IP

          -  Women who are pregnant, breastfeeding, or plan to become pregnant during the course of
             the study

          -  History of taking OAD medications other than metformin, during the 8 weeks prior to
             screening, or have been on insulin therapy within 1 year of screening (with the
             exception of insulin therapy for rescue or use in gestational diabetes)

          -  Treated with a GLP-1 receptor agonist within 6 months

          -  Have a condition that is a contraindicated for use of exenatide (Bydureon BCise),
             dapagliflozin (Farxiga) or metformin per FDA approved prescribing information

          -  History of diabetic ketoacidosis requiring medical intervention (e.g., emergency room
             visit and/or hospitalization) within 3 month prior to screening

          -  An estimated glomerular filtration rate (eGFR &lt;60 mL/min/1.73 m2 at Screening. A
             one-time repeat measurement is permitted at the discretion of the investigator, if the
             value is not consistent with prior values

          -  History of acute pancreatitis associated or not with using an anti-diabetic drug
             therapy

          -  Active liver disease and/or significant abnormal liver function defined as AST &gt; 2 x
             ULN and/or ALT &gt; 2x ULN and /or serum total bilirubin &gt; 2.0 mg/dl

          -  History of frequent urinary and/or genital mycotic infections as determined by the
             investigator

          -  Uncontrolled thyroid disease as determined by the investigator

          -  Personal or first degree relative(s) history of multiple endocrine neoplasia type 2 or
             medullary thyroid carcinoma

          -  Significant cardiovascular history, as determined per Investigator's discretion

          -  Ingestion of prescription or over-the-counter weight loss medications during the 3
             months prior to screening

          -  Have a known clinically significant gastric emptying abnormality (eg, severe diabetic
             gastroparesis or gastric outlet obstruction) or have undergone gastric bypass
             (bariatric) surgery or restrictive bariatric surgery (eg, Lap-BandÂ®) or chronically
             take drugs that directly reduce gastrointestinal motility

          -  Chronic or repeated intermittent corticosteroid treatment (subjects receiving stable
             doses of replacement corticosteroid therapy may be enrolled)

          -  A history of prior amputation, peripheral vascular disease, or diabetic foot ulcers

          -  History of malignant neoplasms within the past 5 years prior to screening. Basal and
             squamous cell skin cancer and any carcinoma in-situ are allowed

          -  Any condition or clinically significant abnormality, which in the Investigator's
             opinion, may render the patient unable to complete the study or which may pose
             significant risk to the patient or successful completion of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michelle Welch, MD</last_name>
    <phone>2108967772</phone>
    <email>welch.md@consanosa.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregory Danet, BS</last_name>
    <phone>2108967772</phone>
    <email>greg@consanosa.com</email>
  </overall_contact_backup>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>May 30, 2019</last_update_submitted>
  <last_update_submitted_qc>May 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

